Canadian biopharmaceutical firm Aeterna Zentaris has submitted a new drug application (NDA) to the US Food and Drug Administration (FDA) for its ghrelin agonist, macimorelin acetate (AEZS-130), a novel orally-active small molecule. The ...
Tags: Aeterna Zentaris, Medicine
The European Commission and the European Medicines Agency have issued orphan drug designation to PROLOR Biotech's hGH-CTP. The longer-acting version of human growth hormone, hGH-CTP, is being developed to treat growth hormone deficiency. ...
Tags: PROLOR Biotech, hGH-CTP, European Orphan Drug Designation
Aileron Therapeutics has secured the second tranche in its series D financing, meaning the overall total has now reached $42 million (pound 26 million). This payment followed the successful progression of the company's ALRN-5281 lead ...
The US Patent and Trademark Office (USPTO) has granted a patent for the use of Aeterna Zentaris' oral ghrelin agonist, AEZS-130 (EP1572) as a diagnostic test for adult growth hormone deficiency (AGHD). AEZS-130, which has been granted ...
Tags: AEZS-130, growth hormone deficiency, AGHD